Author:
Anwer Md. Khalid,Mohammad Muqtader,Iqbal Muzaffar,Ansari Mohd Nazam,Ezzeldin Essam,Fatima Farhat,Alshahrani Saad M.,Aldawsari Mohammed F.,Alalaiwe Ahmed,Alzahrani Aiman A.,Aldayel Abdullah M.
Funder
Deanship of Scientific research, Prince sattam University
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Hematology
Reference27 articles.
1. Bellin A, Berto P, Themistoclakis S, Chandak A, Giusti P, Cavalli G, Bakshi S, Tessarin M, Deambrosis P, Chinellato A (2019) New oral anti-coagulants versus vitamin K antagonists in highthromboembolic risk patients. PLoS ONE 14:e0222762
2. Kalani C, Awudi E, Alexander T, Udeani G, Surani S (2019) Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Hosp Pract (1995) 47(4):181–185
3. Minematsu K, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S (2019) Real-world outcomes of rivaroxaban treatment in patients with both nonvalvular atrial fibrillation and a history of ischemic stroke/transient ischemic attack. Cerebrovasc Dis 2:1–8
4. Vanassche T, Verhamme P (2013) Rivaroxaban for the treatment of pulmonary embolism. Adv Ther 30:589–606
5. Coleman CI, Baker WL, Meinecke AK, Eriksson D, Martinez BK, Bunz TJ, Alberts MJ (2019) Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. Eur Heart J CardiovascPharmacother. https://doi.org/10.1093/ehjcvp/pvz047
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献